Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Stintzing

Showing results (81-90 of 206) with videos related to

Pageof 21
Sort By:
Clinical Colorectal Cancer|July 7, 2011
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancerClemens Giessen, Sebastian Stintzing, Ruediger Paul Laubender, et al.
Cancers|May 16, 2023
Inflammation-Based Prognostic Scores in Pancreatic Cancer Patients-A Single-Center Analysis of 1294 Patients within the Last DecadeChristopher C M Neumann, François Schneider, Georg Hilfenhaus, et al.
Anti-Cancer Drugs|July 19, 2013
Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levelsSebastian Stintzing, Doris Fischhaber, Charlotte Mook, et al.
Journal of Vascular and Interventional Radiology : JVIR|February 18, 2014
CT fluoroscopy-guided percutaneous fiducial marker placement for CyberKnife stereotactic radiosurgery: technical results and complications in 222 consecutive proceduresChristoph G Trumm, Sophia M Häussler, Alexander Muacevic, et al.
Cancer Research Communications|December 7, 2023
A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT TrialJosep Tabernero, Takayuki Yoshino, Sebastian Stintzing, et al.
Cancers|November 26, 2022
EMT-Related Genes Have No Prognostic Relevance in Metastatic Colorectal Cancer as Opposed to Stage II/III: Analysis of the Randomised, Phase III Trial FIRE-3 (AIO KRK 0306; FIRE-3)Elise Pretzsch, Volker Heinemann, Sebastian Stintzing, et al.
Anti-Cancer Drugs|December 17, 2014
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinibSebastian Gamba, Peter Camaj, Volker Heinemann, et al.
Pharmacogenetics and Genomics|November 8, 2014
Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancerAna Sebio, Armin Gerger, Satoshi Matsusaka, et al.
Cancers|March 28, 2024
Cachexia-Affected Survival Based on Inflammatory Parameters Compared to Complex Conventional Nutritional Assessments in Patients with Pancreatic Cancer and Other Gastrointestinal Tumors-The CONKO 020 InvestigationJohanna W Meyer-Knees, Janina Falkenthal, Dominik Geisel, et al.
Journal of Clinical Medicine|February 24, 2024
VEXAS and Myelodysplastic Syndrome: An Interdisciplinary ChallengeVirginie Kreutzinger, Anne Pankow, Zhivana Boyadzhieva, et al.
Pageof 21

Showing results (81-90 of 206) with videos related to

Sort By:
Pageof 21
Clinical Colorectal Cancer|July 7, 2011
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancerClemens Giessen, Sebastian Stintzing, Ruediger Paul Laubender, et al.
Cancers|May 16, 2023
Inflammation-Based Prognostic Scores in Pancreatic Cancer Patients-A Single-Center Analysis of 1294 Patients within the Last DecadeChristopher C M Neumann, François Schneider, Georg Hilfenhaus, et al.
Anti-Cancer Drugs|July 19, 2013
Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levelsSebastian Stintzing, Doris Fischhaber, Charlotte Mook, et al.
Journal of Vascular and Interventional Radiology : JVIR|February 18, 2014
CT fluoroscopy-guided percutaneous fiducial marker placement for CyberKnife stereotactic radiosurgery: technical results and complications in 222 consecutive proceduresChristoph G Trumm, Sophia M Häussler, Alexander Muacevic, et al.
Cancer Research Communications|December 7, 2023
A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT TrialJosep Tabernero, Takayuki Yoshino, Sebastian Stintzing, et al.
Cancers|November 26, 2022
EMT-Related Genes Have No Prognostic Relevance in Metastatic Colorectal Cancer as Opposed to Stage II/III: Analysis of the Randomised, Phase III Trial FIRE-3 (AIO KRK 0306; FIRE-3)Elise Pretzsch, Volker Heinemann, Sebastian Stintzing, et al.
Anti-Cancer Drugs|December 17, 2014
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinibSebastian Gamba, Peter Camaj, Volker Heinemann, et al.
Pharmacogenetics and Genomics|November 8, 2014
Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancerAna Sebio, Armin Gerger, Satoshi Matsusaka, et al.
Cancers|March 28, 2024
Cachexia-Affected Survival Based on Inflammatory Parameters Compared to Complex Conventional Nutritional Assessments in Patients with Pancreatic Cancer and Other Gastrointestinal Tumors-The CONKO 020 InvestigationJohanna W Meyer-Knees, Janina Falkenthal, Dominik Geisel, et al.
Journal of Clinical Medicine|February 24, 2024
VEXAS and Myelodysplastic Syndrome: An Interdisciplinary ChallengeVirginie Kreutzinger, Anne Pankow, Zhivana Boyadzhieva, et al.
Pageof 21